The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu – long considered to be a pandemic threat – have received shots in the UK and US. The mRNA-1018 shot targets a new strain of the H5N1 strain of the influenza ...

“The first-of-its-kind pivotal trial of an mRNA-based pandemic influenza vaccine underscores the potential of this technology to reshape how we confront emerging pathogens,” said Dr. Richard Hatchett, CEO of CEPI. “If successful, these efforts could transform our ability to respond swiftly and equitably to one of the world’s most enduring threats.”